Antidepressant Treatment of AIDS Related Depression.

Launched by GEIGY PHARMACEUTICALS · Jan 17, 2000

Nctid: NCT00000390

Payload: {"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-09-05"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D000003863", "term"=>"Depression"}, {"id"=>"D000003866", "term"=>"Depressive Disorder"}], "ancestors"=>[{"id"=>"D000001526", "term"=>"Behavioral Symptoms"}, {"id"=>"D000019964", "term"=>"Mood Disorders"}, {"id"=>"D000001523", "term"=>"Mental Disorders"}], "browseLeaves"=>[{"id"=>"M16355", "name"=>"Syndrome", "relevance"=>"LOW"}, {"id"=>"M7058", "name"=>"Depression", "asFound"=>"Depression", "relevance"=>"HIGH"}, {"id"=>"M7061", "name"=>"Depressive Disorder", "asFound"=>"Depression", "relevance"=>"HIGH"}, {"id"=>"M18250", "name"=>"HIV Infections", "relevance"=>"LOW"}, {"id"=>"M3522", "name"=>"Acquired Immunodeficiency Syndrome", "relevance"=>"LOW"}, {"id"=>"M10199", "name"=>"Immunologic Deficiency Syndromes", "relevance"=>"LOW"}, {"id"=>"M4818", "name"=>"Behavioral Symptoms", "relevance"=>"LOW"}, {"id"=>"M21835", "name"=>"Mood Disorders", "relevance"=>"LOW"}, {"id"=>"M4815", "name"=>"Mental Disorders", "relevance"=>"LOW"}, {"id"=>"M14473", "name"=>"Psychotic Disorders", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Symptoms and General Pathology", "abbrev"=>"BC23"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Behaviors and Mental Disorders", "abbrev"=>"BXM"}, {"name"=>"Infections", "abbrev"=>"BC01"}, {"name"=>"Urinary Tract, Sexual Organs, and Pregnancy Conditions", "abbrev"=>"BXS"}, {"name"=>"Immune System Diseases", "abbrev"=>"BC20"}]}, "interventionBrowseModule"=>{"meshes"=>[{"id"=>"D000007099", "term"=>"Imipramine"}], "ancestors"=>[{"id"=>"D000000929", "term"=>"Antidepressive Agents, Tricyclic"}, {"id"=>"D000000928", "term"=>"Antidepressive Agents"}, {"id"=>"D000011619", "term"=>"Psychotropic Drugs"}, {"id"=>"D000018759", "term"=>"Adrenergic Uptake Inhibitors"}, {"id"=>"D000014179", "term"=>"Neurotransmitter Uptake Inhibitors"}, {"id"=>"D000049990", "term"=>"Membrane Transport Modulators"}, {"id"=>"D000045504", "term"=>"Molecular Mechanisms of Pharmacological Action"}, {"id"=>"D000018663", "term"=>"Adrenergic Agents"}, {"id"=>"D000018377", "term"=>"Neurotransmitter Agents"}, {"id"=>"D000045505", "term"=>"Physiological Effects of Drugs"}], "browseLeaves"=>[{"id"=>"M10147", "name"=>"Imipramine", "asFound"=>"Locked", "relevance"=>"HIGH"}, {"id"=>"M4247", "name"=>"Antidepressive Agents", "relevance"=>"LOW"}, {"id"=>"M4248", "name"=>"Antidepressive Agents, Tricyclic", "relevance"=>"LOW"}, {"id"=>"M14474", "name"=>"Psychotropic Drugs", "relevance"=>"LOW"}, {"id"=>"M20746", "name"=>"Adrenergic Agents", "relevance"=>"LOW"}, {"id"=>"M20504", "name"=>"Neurotransmitter Agents", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Psychotropic Drugs", "abbrev"=>"PsychDr"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE2"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"primaryPurpose"=>"TREATMENT"}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2000-04", "lastUpdateSubmitDate"=>"2015-04-22", "studyFirstSubmitDate"=>"2000-01-17", "studyFirstSubmitQcDate"=>"2000-01-17", "lastUpdatePostDateStruct"=>{"date"=>"2015-04-23", "type"=>"ESTIMATED"}, "studyFirstPostDateStruct"=>{"date"=>"2000-01-18", "type"=>"ESTIMATED"}}, "conditionsModule"=>{"keywords"=>["Adult", "Acquired Immunodeficiency Syndrome", "Depression", "Female", "Human", "Imipramine", "Male", "Middle Age", "Acquired Immunodeficiency Syndrome -- *complications", "Depression -- *drug therapy", "Depression -- etiology", "Imipramine -- *therapeutic use"], "conditions"=>["Depression"]}, "descriptionModule"=>{"briefSummary"=>"To test the effectiveness treating AIDS related depression with imipramine hydrochloride.\n\nDepression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.\n\nThis is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.", "detailedDescription"=>"To test the effectiveness treating AIDS related depression with imipramine hydrochloride.\n\nDepression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.\n\nThis is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT", "OLDER_ADULT"], "maximumAge"=>"65 years", "minimumAge"=>"18 years", "eligibilityCriteria"=>"Inclusion Criteria:\n\n* Patient must be ambulatory and relatively good health. Even if unable to work at least able to partially care care for self and not demented.\n* May have been alcoholic or drug abuser 6 months previous.\n* Unspecified\n* CD4 Unspecified.\n\nExclusion Criteria:\n\n* Non ambulatory patients or those requiring extensive help in self care are excluded.\n* Non ambulatory patients or those requiring extensive help in self care are excluded.\n* Current alcohol or drug abuse.\n* Unspecified"}, "identificationModule"=>{"nctId"=>"NCT00000390", "briefTitle"=>"Antidepressant Treatment of AIDS Related Depression.", "organization"=>{"class"=>"NIH", "fullName"=>"National Institute of Mental Health (NIMH)"}, "orgStudyIdInfo"=>{"id"=>"R01MH042952", "link"=>"https://reporter.nih.gov/quickSearch/R01MH042952", "type"=>"NIH"}, "secondaryIdInfos"=>[{"id"=>"87-DEP", "type"=>"OTHER", "domain"=>"GEIGY Pharmaceuticals"}]}, "armsInterventionsModule"=>{"interventions"=>[{"name"=>"Imipramine hydrochloride", "type"=>"DRUG"}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"10021", "city"=>"New York", "state"=>"New York", "country"=>"United States", "facility"=>"New York Hosp - Cornell Med Ctr", "geoPoint"=>{"lat"=>40.71427, "lon"=>-74.00597}}], "overallOfficials"=>[{"name"=>"Frances A", "role"=>"STUDY_CHAIR"}, {"name"=>"Manning D", "role"=>"STUDY_CHAIR"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"GEIGY Pharmaceuticals", "class"=>"INDUSTRY"}}}}